Insider Monkey
CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting
📊
AI Sentiment
Positive
7/10
- Home
- ACLX
ACLX
Arcellx Inc.
as of 12-05-2025 3:45pm EST
$68.70
+$0.24
+0.36%
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
Chart Type:
Time Range:
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 4.2B | IPO Year: | 2022 |
| Target Price: | $115.50 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $47.86 - $94.07 | Next Earning Date: | 11-05-2025 |
| Revenue: | $35,898,000 | Revenue Growth: | -76.96% |
| Revenue Growth (this year): | -68.36% | Revenue Growth (next year): | 302.49% |
AI-Powered ACLX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 71.71%
71.71%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Arcellx Inc. (ACLX)
Heery Christopher
Sell
CHIEF MEDICAL OFFICER
ACLX Nov 17, 2025
Avg Cost/Share
$90.00
Shares
340
Total Value
$30,600.00
Owned After
284
SEC Form 4
Gilson Michelle
Sell
CHIEF FINANCIAL OFFICER
ACLX Oct 15, 2025
Avg Cost/Share
$91.04
Shares
5,364
Total Value
$488,315.49
Owned After
8,466
SEC Form 4
Gilson Michelle
Sell
CHIEF FINANCIAL OFFICER
ACLX Oct 6, 2025
Avg Cost/Share
$86.22
Shares
1,064
Total Value
$91,733.29
Owned After
8,466
SEC Form 4
Gilson Michelle
Sell
CHIEF FINANCIAL OFFICER
ACLX Oct 3, 2025
Avg Cost/Share
$86.00
Shares
4,882
Total Value
$419,869.58
Owned After
8,466
SEC Form 4
Heery Christopher
Sell
CHIEF MEDICAL OFFICER
ACLX Sep 30, 2025
Avg Cost/Share
$81.40
Shares
21,034
Total Value
$1,709,722.59
Owned After
284
Heery Christopher
Sell
CHIEF MEDICAL OFFICER
ACLX Sep 29, 2025
Avg Cost/Share
$80.16
Shares
73
Total Value
$5,851.68
Owned After
284
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Nov 17, 2025 | Sell | $90.00 | 340 | $30,600.00 | 284 | |
| Gilson Michelle | ACLX | CHIEF FINANCIAL OFFICER | Oct 15, 2025 | Sell | $91.04 | 5,364 | $488,315.49 | 8,466 | |
| Gilson Michelle | ACLX | CHIEF FINANCIAL OFFICER | Oct 6, 2025 | Sell | $86.22 | 1,064 | $91,733.29 | 8,466 | |
| Gilson Michelle | ACLX | CHIEF FINANCIAL OFFICER | Oct 3, 2025 | Sell | $86.00 | 4,882 | $419,869.58 | 8,466 | |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Sep 30, 2025 | Sell | $81.40 | 21,034 | $1,709,722.59 | 284 | |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Sep 29, 2025 | Sell | $80.16 | 73 | $5,851.68 | 284 |
Latest Arcellx Inc. News
ACLX Breaking Stock News: Dive into ACLX Ticker-Specific Updates for Smart Investing
Compare ACLX vs Leading Stocks
See how ACLX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ACLX Arcellx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.